Sanofi reported that efdoralprin alfa—an experimental recombinant protein acquired in its Inhibrx buyout—met primary and key secondary endpoints in a Phase 2 study for alpha‑1 antitrypsin deficiency (AATD). The drug produced superior increases in protective AAT protein levels versus plasma‑derived therapy with a similar safety profile, according to company statements. Sanofi plans to present the data at a medical meeting and engage regulators on next steps. Management positions the result as validation of the strategic acquisition and a pathway to a new therapeutic option in a rare disease with limited treatment alternatives.